Quantitative analysis uncovers O-GlcNAc modifications in hepatocellular carcinoma, suggesting new therapeutic targets.
O-linked β-N-acetylglucosamine (O-GlcNAc) modification (O-GlcNAcylation) underlies the pathogenesis of multiple cancers, including hepatocellular carcinoma (HCC). However, comprehensive and quantitative characterization of site-specific O-GlcNAcylation at the proteome scale remains technically challenging. Here, we employed an integrated workflow for the quantitative O-GlcNAc proteomics of HCC and controls. Proteins from liver samples were subjected to chemoenzymatic labeling, photocleavable alkyne-biotin-based enrichment, proteolytic digestion, and isotopic labeling with tandem mass tags. The O-GlcNAc peptides were analyzed by a nanoUPLC-MS/MS system in HCD product-dependent EThcD (HCD-pd-EThcD) mode for site mapping and quantification. A total of 440 O-GlcNAc peptides, representing 305 sites on 196 proteins, were confidently identified. Differential analysis revealed 190 O-GlcNAc peptides from 121 proteins significantly upregulated in HCC after normalization to their corresponding protein abundance. Functional enrichment and protein-protein interaction analyses indicate that proteins with increased levels of O-GlcNAcylation are involved in nuclear transport, transcriptional regulation, and ATP-dependent chromatin remodeling. Our work provides quantitative proteomic insights into O-GlcNAcylation in HCC, revealing global upregulation and functional clustering of O-GlcNAc-modified proteins. These findings will help elucidate the functional roles of O-GlcNAcylation in liver cancer, facilitating the development of novel therapeutics and sensitive biomarkers.
No takes yet. Share an insight, caveat, or question.
Hou et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: